A kind of RG108 tetravalent platinum and its preparation method and application
By coordinating RG108 with platinum compounds, the ototoxicity and liver and nephrotoxicity of cisplatin was solved, and the anti-tumor effect was improved. The combined use of DNA methylation inhibitors was achieved to achieve tumors effective treatment and toxicity reduction.
Patent Information
- Application Number
- CN202411141881.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-08-20
AI Technical Summary
Cisplatin, as a platinum anticancer drug, has toxic side effects such as ototoxicity and liver and kidney toxicity, which limits its clinical application. The DNA methylation inhibitor decitabine is cytotoxic and instability, making it difficult to develop low ototoxicity, Drugs with high anti-tumor activity.
Synthesis of RG108 tetravalent platinum by coupling RG108 with platinum compounds (cisplatin or oxaliplatin) to form a single R platinum complex or a biR platinum complex. The specific synthesis steps and purification methods are used to prepare the Improved properties of RG108 tetravalent platinum.
RG108 tetravalent platinum significantly reduces the ototoxicity and liver and kidney toxicity of platinum drugs, improves the killing effect on tumor cells, reduces hearing damage, enhances the protection effect of liver and kidney, and is used in combination with DNA methylation inhibitors. A synergistic anti-tumor effect has been achieved.
Smart Images

Figure CN118666911B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug synthesis, and particularly relates to RG108 tetravalent platinum and a preparation method and application thereof. Background Art
[0002] Platinum drugs are one of the most widely used broad-spectrum anti-tumor drugs in clinical practice. Although targeted drugs, immunosuppressants, etc. have become hot spots in the research and development of anti-tumor drugs in recent years, cisplatin, as the first-generation platinum anticancer drug, is still the cornerstone of the treatment of various solid tumors such as ovarian cancer, cervical cancer, lung cancer, prostate cancer, nasopharyngeal carcinoma and breast cancer. However, toxic side effects such as ototoxicity, hepatotoxicity, renal toxicity and gastrointestinal toxicity have greatly limited the clinical application of cisplatin. Cisplatin is mainly excreted through the kidneys. If renal function is impaired, the drug is difficult to be effectively excreted, resulting in an increased possibility of poisoning, which in turn increases the risk of hearing impairment. This hearing impairment is usually irreversible and can lead to progressive and bilateral sensorineural hearing loss. For adult patients, ototoxicity will reduce the patient's quality of life; for children, this hearing loss will further affect their language and mental development.
[0003] In order to reduce the occurrence of toxic side effects, the risk of toxicity is usually reduced clinically by adjusting the dose of cisplatin and using other drugs. At the same time, the patient's hearing and liver and kidney function are closely monitored and evaluated regularly to ensure patient safety and maximize drug efficacy. However, the toxic side effects of cisplatin are still unavoidable.
[0004] DNA methylation is one of the most widely studied epigenetic mechanisms. Its related DNA methyltransferases (DNMTs) are overexpressed in a variety of human tumors, triggering hypermethylation of the promoter regions of certain cancer suppressor genes, thereby silencing cancer suppressor genes and causing cell carcinogenesis. DNA methyltransferase inhibitors (DNMTi) can specifically inhibit the activity of DNMTs, thereby inhibiting the occurrence of abnormal DNA methylation and the activation of silenced cancer suppressor genes to prevent and treat cancer, and are therefore an important direction in the development of anti-tumor drugs.
[0005] Decitabine is a nucleotide DNMT inhibitor that was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of hematological malignancies and has achieved encouraging efficacy in solid tumors, but it has disadvantages such as cytotoxicity and instability.
[0006] RG108 is a novel non-nucleotide small molecule DNMTs inhibitor that can significantly inhibit DNA methylation and has no cytotoxicity because it does not need to be integrated into DNA to work. Studies have found that RG108 can induce apoptosis of tumor cells and inhibit their proliferation, and has anti-tumor effects.
[0007] In summary, it is necessary to develop a drug candidate with low ototoxicity and high antitumor activity. Summary of the invention
[0008] One of the purposes of the present invention is to provide a RG108 tetravalent platinum to solve the problems raised in the above background technology.
[0009] In order to achieve the above technical objectives, the technical solution of the present invention is:
[0010] A RG108 tetravalent platinum is obtained by connecting and coordinating RG108 with a platinum compound, wherein the platinum compound is cisplatin or oxaliplatin.
[0011] As an improvement, the RG108 tetravalent platinum includes a single R platinum complex containing one RG108 group or a double R platinum complex containing two RG108 groups;
[0012] The general structural formula of the single R platinum complex is: ;
[0013] The general structural formula of the double R platinum complex is: ;
[0014] Wherein, the R is a RG108 group, and the RG108 group is: .
[0015] As a further improvement, the RG108 tetravalent platinum is one of the following structural formulas: .
[0016] Another object of the present invention is to provide a method for preparing RG108 tetravalent platinum, comprising the following steps:
[0017] S1. Synthesis of Hydroxyplatinum
[0018] Weigh cisplatin or oxaliplatin, slowly add hydrogen peroxide, protect from light, heat and reflux at 75°C for 4 hours, after the reaction is completed, stand at 5°C for crystallization, centrifuge, wash the solid after centrifugation with distilled water, ethanol, and ether twice each, and dry to obtain yellow solid cisplatin hydroxyplatin and white solid oxaliplatin hydroxyplatin;
[0019] The reaction equation is:
[0020] Synthesis of tetravalent platinum S2 and RG108
[0021] Synthesis of Disubstituted Tetravalent Platinum with S21 and RG108
[0022] Weigh the cisplatin hydroxyplatinum or oxaliplatin hydroxyplatinum, add the solvent DMF, then add RG108, triethylamine and TBTU in sequence, protect from light, under nitrogen protection, stir at room temperature until the reaction liquid is clear, add ice water to the reaction liquid to precipitate a yellow precipitate, and filter to obtain RG108 disubstituted cisplatin or RG108 disubstituted oxaliplatin;
[0023] The reaction equation is:
[0024] Synthesis of Monosubstituted Tetravalent Platinum with S22 and RG108
[0025] Add RG108, triethylamine and TBTU to DMSO, stir at room temperature for 20 minutes, then add the cisplatin hydroxyplatinum or oxaliplatin hydroxyplatinum, protect from light, stir at room temperature under nitrogen protection until the reaction solution is clear, add ice water to the reaction solution to precipitate a yellow precipitate, and filter to obtain RG108 monosubstituted cisplatin or RG108 monosubstituted oxaliplatin;
[0026] The reaction equation is:
[0027] Purification of S3, RG108 tetravalent platinum
[0028] Method 1
[0029] RG108 mono-substituted cisplatin, RG108 di-substituted cisplatin and RG108 di-substituted oxaliplatin were purified by silica gel column, and gradient eluted with a mixture of dichloromethane and methanol to obtain RG108 tetravalent platinum;
[0030] Method 2
[0031] The RG108 monosubstituted oxaliplatin was washed twice with methanol and twice with dichloromethane to obtain RG108 tetravalent platinum.
[0032] Furthermore, in step S1, the molar ratio of the cisplatin or the oxaliplatin to the hydrogen peroxide is 1:43.84.
[0033] Furthermore, in step S1, the mass concentration of the hydrogen peroxide is 30%.
[0034] Furthermore, in step S21, the molar ratio of the cisplatin hydroxyplatinum or the oxaliplatin hydroxyplatinum to RG108, triethylamine and TBTU is 1:3:3:3; in step S22, the molar ratio of the cisplatin hydroxyplatinum or the oxaliplatin hydroxyplatinum to RG108, triethylamine and TBTU is 1.1:1:3:3.
[0035] Furthermore, in step S3, the volume ratio of dichloromethane to methanol in the dichloromethane and methanol mixture is 15:1.
[0036] Another object of the present invention is to provide the use of RG108 tetravalent platinum in the preparation of anti-tumor drugs, hearing protectants, and liver and kidney protectants.
[0037] Furthermore, the tumors include non-small cell lung cancer, cervical cancer, breast cancer, pharyngeal squamous cell carcinoma, colon cancer and liver cancer cells.
[0038] Due to the adoption of the above technical solution, the beneficial effects of the present invention are:
[0039] The RG108 tetravalent platinum provided by the present invention not only solves the shortcomings of poor pharmacokinetics and congenital or acquired drug resistance of platinum drugs, but also solves the problem of obvious toxic and side effects such as ototoxicity induced by platinum drugs. The RG108 tetravalent platinum has an ear-protective effect, and at the same time alleviates the hepato-kidney toxicity caused by platinum drugs, and has a liver-kidney protective effect.
[0040] RG108 tetravalent platinum increases the killing effect of platinum drugs on tumor cells by increasing drug uptake by tumor cells. At the same time, the accumulation of RG108 tetravalent platinum in the cochlea is reduced, and the hearing threshold of mice RG108 tetravalent platinum is also significantly lower than that of cisplatin, indicating that RG108 tetravalent platinum reverses the damage of platinum drugs to hearing. This feature allows RG108 tetravalent platinum to better protect patients' hearing while improving the effect of tumor treatment.
[0041] RG108 tetravalent platinum can be used in combination with chemotherapy and DNA methylation inhibitors for anti-cancer and anti-tumor treatment. While reversing tumor growth and killing tumors, RG108 tetravalent platinum can also alleviate cisplatin-induced ototoxicity and reduce accumulation in the liver and kidneys, thereby playing a synergistic role in anti-tumor effects. RG108 tetravalent platinum also has a good effect in improving noise-induced hearing loss. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0043] Figure 1 is the high resolution mass spectrum (HRMS) of cisplatin hydroxyplatin in Example 1;
[0044] Figure 2 is the high resolution mass spectrum (HRMS) of oxaliplatin hydroxyplatin in Example 2;
[0045] Figure 3 This is the NMR hydrogen spectrum of RG108 disubstituted cisplatin ( 1 H-NMR);
[0046] Figure 4 This is the NMR carbon spectrum of RG108 disubstituted cisplatin ( 13 C-NMR);
[0047] Figure 5 This is the high-resolution mass spectrum (HRMS) of RG108 disubstituted cisplatin;
[0048] Figure 6 This is the NMR hydrogen spectrum of RG108 disubstituted oxaliplatin ( 1 H-NMR);
[0049] Figure 7 This is the NMR carbon spectrum of RG108 disubstituted oxaliplatin ( 13 C-NMR);
[0050] Figure 8 It is the high-resolution mass spectrum (HRMS) of RG108 disubstituted oxaliplatin;
[0051] Fig. 9 This is the NMR hydrogen spectrum of RG108 monosubstituted cisplatin ( 1 H-NMR);
[0052] Fig.10 This is the NMR carbon spectrum of RG108 monosubstituted cisplatin ( 13 C-NMR);
[0053] Fig.11 is the high-resolution mass spectrum (HRMS) of RG108 monosubstituted cisplatin;
[0054] Fig.12 This is the H NMR spectrum of RG108 monosubstituted oxaliplatin ( 1 H-NMR);
[0055] Fig.13 This is the NMR carbon spectrum of RG108 monosubstituted oxaliplatin ( 13 C-NMR);
[0056] Fig.14 It is the high-resolution mass spectrum (HRMS) of RG108 monosubstituted oxaliplatin;
[0057] Fig.15 This is the result of anti-tumor experiment in mice;
[0058] Fig.16 These are the hearing test results of mice treated with RG108 tetravalent platinum, cisplatin, and oxaliplatin;
[0059] Fig.17 It is the result of platinum accumulation in mouse tissues after administration of cisplatin and RG108 tetravalent platinum;
[0060] Fig.18 These are the serum index results of mouse tissues after administration of cisplatin and RG108 tetravalent platinum;
[0061] Fig.19 These are the HE results of mouse tissues after administration of cisplatin and RG108 tetravalent platinum. DETAILED DESCRIPTION
[0062] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0063] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0064] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0065] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0066] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0067] Example 1 Preparation of cisplatin hydroxyplatin: 200 mg (0.67 mmol) of cisplatin was accurately weighed into a round-bottom flask using an analytical balance, and 3 mL (29.37 mmol) of hydrogen peroxide with a mass concentration of 30 wt% was slowly added. The round-bottom flask was protected from light with tin foil and refluxed at 75°C for 4 hours. After the reaction was complete, the round-bottom flask was placed in a 5°C refrigerator to stand for crystallization. The solid obtained after filtration was washed twice with 5 mL of distilled water, 5 mL of ethanol, and 5 mL of ether. The solid was then placed in a vacuum drying oven and dried overnight at 45°C to obtain a light yellow solid cisplatin hydroxyplatin. The yield of cisplatin hydroxyplatin was 84.7%. Figure 1 The following is the high resolution mass spectrum of cisplatin hydroxyplatin, HRMS (m / z): calcd for C l2 H9N2O2Pt[M+H] + , 333.9689; found, 333.9704.
[0068] Example 2 Preparation of Oxaliplatin Hydroxyplatin: 266 mg (0.67 mmol) of oxaliplatin was accurately weighed into a round-bottom flask using an analytical balance, and 3 mL (29.37 mmol) of hydrogen peroxide with a mass concentration of 30 wt% was slowly added. The round-bottom flask was protected from light with tin foil, and refluxed at 75°C for 4 hours. After the reaction was complete, the round-bottom flask was placed in a 5°C refrigerator for crystallization. The solid obtained after filtration was washed twice with 5 mL of distilled water, 5 mL of ethanol, and 5 mL of ether, and then the solid was placed in a vacuum drying oven at 45°C and dried overnight to obtain white solid oxaliplatin hydroxyplatin. The yield of oxaliplatin hydroxyplatin was 87.8%. Figure 2 The following is the high resolution mass spectrum of oxaliplatin hydroxyplatin, HRMS (m / z): calcd for C8H 17 N2O6Pt[M+H] + , 432.0729; found, 432.0740.
[0069] Example 3 Preparation of RG108 disubstituted cisplatin: 100 mg (0.3 mmol) of cisplatin hydroxyplatinum prepared in Example 1 was accurately weighed into a round-bottom flask using an analytical balance, 2 ml of anhydrous DMF was added, and 300 mg (0.9 mmol) of RG108, 130 μL (0.9 mmol) of triethylamine, and 288 mg (0.9 mmol) of TBTU were added in sequence, with triethylamine and TBTU being catalysts. The round-bottom flask was protected from light with tin foil, evacuated, replaced with a nitrogen balloon three times and protected, stirred at 50°C for 12 hours until the reaction solution was clear, then ice water was added to the reaction solution to precipitate, and RG108 disubstituted cisplatin crude was obtained after filtration; the RG108 disubstituted cisplatin crude was re-dissolved with methanol, mixed with silica gel, and the solid after evaporation was separated and purified by silica gel column, and gradient elution was performed using a mixture of dichloromethane and methanol as an eluent, the volume ratio of dichloromethane to methanol in the eluent was 15:1, the product was collected, dried, and finally purified yellow solid RG108 disubstituted cisplatin was obtained with a yield of 58.4%.
[0070] pass 1 H-NMR, 13 The obtained product was characterized by C-NMR and HRMS, and the data are as follows:
[0071] 1 H-NMR (400MHz, DMSO-D6) δ: 10.74 (s, 2H), 7.80 (s, 8H), 7.49 (d, J=4.0Hz, 2H), 7.26 (d, J=8.0Hz, 2H), 7.00 (s, 4H), 6.94 (d, J=4.0Hz, 2H), 6.54 (s, 6H), 5.20 (s, 2H), 3.61 (s, 4H).
[0072] 13 C-NMR (101MHz, DMSO-D6) δ: 176.43, 167.96, 136.60, 135.21, 131.60, 127.43, 123.69, 123.60, 121.49, 118.83, 118.45, 111.99, 110.86, 54.28, 25.43.
[0073] HRMS (m / z): calculate for C 38 H 32 N6O8Cl2NaPt + ([(M+Na)] + ): 988.1199; found: 988.1228.
[0074] pass 1 H-NMR, 13C-NMR and HRMS results confirmed that the obtained compound was RG108 disubstituted cisplatin.
[0075] RG108 double substituted cisplatin 1 H-NMR images Figure 3 As shown, RG108 double substituted cisplatin 13 C-NMR images Figure 4 As shown, the HRMS image of RG108 disubstituted cisplatin is as follows Figure 5 shown.
[0076] Example 4 Preparation of RG108 disubstituted oxaliplatin: 129 mg (0.3 mmol) of oxaliplatin hydroxyplatinum prepared in Example 2 was accurately weighed into a round-bottom flask using an analytical balance, 2 ml of anhydrous DMF was added, and 300 mg (0.9 mmol) of RG108, 130 μL (0.9 mmol) of triethylamine, and 288 mg (0.9 mmol) of TBTU were added in sequence. Triethylamine and TBTU were used as catalysts. The round-bottom flask was protected from light with tin foil, evacuated, replaced with a nitrogen balloon three times and protected, stirred at 50°C for 12 hours until the reaction solution was clear, ice water was added to the reaction solution to precipitate, the precipitate was redissolved with methanol, mixed with silica gel, and the solid after evaporation was separated and purified by silica gel column, and gradient elution was performed using a mixture of dichloromethane and methanol as an eluent, the volume ratio of dichloromethane to methanol in the eluent was 15:1, the product was collected and dried, and finally the purified yellow solid RG108 disubstituted oxaliplatin was obtained with a yield of 51.2%.
[0077] pass 1 H-NMR, 13 The obtained product was characterized by C-NMR and HRMS, and the data are as follows:
[0078] 1 H-NMR (400MHz, DMSO) δ: 10.67 (s, 2H), 8.37 (s, 2H), 7.89 (s, 1H), 7.71-7.77 (m, 9H), 7.47 (dd, 2H), 7.21 (d, 2H), 6.95-6.99 (m, 2H), 6.87-6.92 (m, 4H), 5.22-5. 26 (m, 1H), 5.18 (q, 1H), 3.46-3.67 (m, 4H), 2.65 (s, 2H), 2.05-2.18 (m, 2H), 1.38-1.5 (m, 4H), 1.06 (s, 2H).
[0079] 13C-NMR (101MHz, DMSO-D6) δ: 175.31, 167.85, 164.26, 136.57, 135.17, 131.56, 127.42, 123.69, 121.50, 118.81, 118.63, 118.48, 111.98, 110.77, 61.49, 54.43, 25.45, 25.38, 24.20.
[0080] HRMS (m / z): calculate for C 46 H 40 N6O 12 NaPt + ([(M+Na)] + ): 1086.2244; found: 1086.2246.
[0081] pass 1 H-NMR, 13 C-NMR and HRMS results confirmed that the obtained compound was RG108 disubstituted oxaliplatin.
[0082] RG108 double substituted oxaliplatin 1 H-NMR images Figure 6 As shown, RG108 disubstituted oxaliplatin 13 C-NMR images Figure 7 As shown, the HRMS image of RG108 disubstituted oxaliplatin is as follows Figure 8 shown.
[0083] Example 5 Preparation of RG108 monosubstituted cisplatin: 300 mg (0.9 mmol) of RG108 and 288 mg (0.9 mmol) of TBTU were accurately weighed into a 25 ml round-bottom flask using an analytical balance, 2 ml of DMSO was added to dissolve, and 130 μL (0.9 mmol) of triethylamine was added. After stirring at room temperature for 20 minutes, 110 mg (0.33 mmol) of the cisplatin hydroxyplatinum in Example 1 was weighed and added to the reaction solution. The round-bottom flask was protected from light with tin foil, evacuated, replaced with a nitrogen balloon three times and protected, stirred at 50°C for 24 hours until the reaction solution was clear, ice water was added to the reaction solution to precipitate, the precipitate was redissolved with methanol, mixed with silica gel, and the evaporated solid was separated and purified by silica gel column, and gradient elution was performed using a mixture of dichloromethane and methanol as an eluent, the volume ratio of dichloromethane to methanol in the eluent was 15:1, the product was collected and dried, and finally the purified yellow solid RG108 monosubstituted cisplatin was obtained with a yield of 35.2%.
[0084] pass 1 H-NMR, 13 The obtained product was characterized by C-NMR and HRMS, and the data are as follows:
[0085] 1 H-NMR (400MHz, DMSO-D6) δ: 10.70 (s, 1H), 7.76 (s, 4H), 7.43 (s, 1H), 7.22 (s, 1H), 6.92 (d, 3H), 5.94 (m, 6H), 5.01 (s, 1H), 3.55 (s, 2H).
[0086] 13 C-NMR (101MHz, DMSO-D6) δ: 176.40, 168.14, 136.59, 135.10, 131.72, 127.52, 123.58, 123.45, 121.42, 118.77, 118.43, 111.95, 111.31, 55.17, 25.45.
[0087] HRMS (m / z): calculate for C 19 H 21 N4O5Cl2NaPt + ([(M+Na)] + ): 650.0531; found: 650.0546.
[0088] pass 1 H-NMR, 13 C-NMR and HRMS results confirmed that the obtained compound was RG108 monosubstituted cisplatin.
[0089] RG108 monosubstituted cisplatin 1 H-NMR images Fig. 9 As shown, RG108 monosubstituted cisplatin 13 C-NMR images Fig.10 As shown, the HRMS image of RG108 monosubstituted cisplatin is as follows Fig.11 shown.
[0090] Example 6 Preparation of RG108 monosubstituted oxaliplatin: 300 mg (0.9 mmol) of RG108 and 288 mg (0.9 mmol) of TBTU were accurately weighed in a 25 ml round-bottom flask using an analytical balance, 2 ml of DMSO was added to dissolve, and 130 μL (0.9 mmol) of triethylamine was added. After stirring at room temperature for 20 minutes, 142 mg (0.33 mmol) of oxaliplatin hydroxyplatinum in Example 2 was weighed and added to the reaction solution. The round-bottom flask was protected from light with tin foil, evacuated, replaced with a nitrogen balloon three times and protected, stirred at 50° C. for 24 hours until the reaction solution was clear, ice water was added to the reaction solution to precipitate, the precipitate was washed twice with 2 ml of methanol and 2 ml of dichloromethane, the product was collected, and dried to obtain the purified yellow solid RG108 monosubstituted oxaliplatin with a yield of 31.2%.
[0091] pass 1 H-NMR, 13 The obtained product was characterized by C-NMR and HRMS, and the data are as follows:
[0092] 1 H-NMR (400MHz, DMSO-D6) δ: 10.64 (s, 1H), 8.03 (s, 1H), 7.85-7.88 (m, 1H), 7.69-7.76 (m, 5H), 7.42 (q, 1H), 7.20 (d, 1H), 7.07 (d, 1H), 6.89-6.97 (m, 2H) , 6.85-6.89 (m, 1H), 4.99-5.06 (m, 1H), 3.42-3.59 (m, 2H), 1.96-2.08 (m, 2H), 1.02-1.47 (m, 8H).
[0093] 13 C-NMR (101MHz, DMSO-D6) δ: 176.34, 167.94, 164.39, 136.55, 135.08, 131.66, 127.50, 123.62, 121.44, 118.78, 118.49, 118.41, 111.93, 111.07, 61.80, 60.71, 55.24, 31.31, 25.45, 24.19.
[0094] HRMS (m / z): calculate for C 27 H 28 N4O9NaPt + ([(M+Na)] + ): 770.1396; found: 770.1418.
[0095] pass 1H-NMR, 13 C-NMR and HRMS results confirmed that the obtained compound was RG108 monosubstituted oxaliplatin.
[0096] RG108 single substitution of oxaliplatin 1 H-NMR images Fig.12 As shown, RG108 single-substituted oxaliplatin 13 C-NMR images Fig.13 As shown, the HRMS image of RG108 monosubstituted oxaliplatin is as follows Fig.14 shown.
[0097] Example 7 The CCK8 method was used to conduct an in vitro anti-tumor effect experiment of RG108 tetravalent platinum. The specific method is as follows: A549 (human non-small cell lung cancer cells), HeLa (human cervical cancer cells), Fadu (human pharyngeal squamous cells), MDA-MB-231 (human breast cancer cells), HCT116 (human colon cancer cells), PLC (human liver cancer cells), and L02 (human liver cells) were selected. Cells in the logarithmic growth phase were collected, the cell concentration was adjusted, and inoculated into a 96-well plate (about 3000 cells / well), 100 μL per well, and the outermost edge wells of the 96-well plate were filled with sterile PBS to reduce the influence of the edge effect.
[0098] The cells were cultured overnight at 37°C and 5% CO2. When the cells adhered to the wall, the drugs with gradient concentrations were added. Three replicate wells were set for each concentration. After 48 hours of drug action, 10 μL of 5 mg / mL CCK8 was added. The cells were protected from light and incubated for another 1.5 hours. The absorbance A value of each well at 425 nm was measured by an ELISA reader. The experiment was repeated three times independently to calculate the inhibition rate of the cells at each concentration. The data were processed using SPSS 16.0 statistical software. IC 50 The results are shown in Table 1.
[0099] The cell inhibition rate calculation formula is:
[0100] Cell inhibition rate (%) = (ODtreated-ODblank) / (ODcontrol-ODblank) × 100%
[0101]
[0102] In Table 1, CDDP is cisplatin, L-OHP is oxaliplatin, RG108 is a DNMT nucleoside analog, RG108-CDDP is RG108 monosubstituted cisplatin, 2RG108-CDDP is RG108 disubstituted cisplatin, RG108-L-OHP is RG108 monosubstituted oxaliplatin, 2RG108-L-OHP is RG108 disubstituted oxaliplatin, RG108+CDDP (1:1) is a mixed solution of RG108 and cisplatin with a molar ratio of 1:1, RG108+CDDP (2:1) is a mixed solution of RG108 and cisplatin with a molar ratio of 2:1, RG108+L-OHP (1:1) is a mixed solution of RG108 and oxaliplatin with a molar ratio of 1:1, and RG108+L-OHP (2:1) is a mixed solution of RG108 and oxaliplatin with a molar ratio of 2:1.
[0103] The experimental results showed that RG108 double-substituted cisplatin tetravalent platinum had a significant inhibitory effect on all tumor cells, especially in Fadu cells, with IC 50 The IC of RG108 disubstituted oxaliplatin in A549, Fadu, and MDA-MB-231 cells was only 1 / 500 of that in cisplatin and much lower than that in the combination group. 50 The lowest, better than oxaliplatin, RG108 single-substituted oxaliplatin and combination drug groups; but in other cells, oxaliplatin quadrivalent platinum did not show obvious inhibitory advantages.
[0104] Example 8 Experiment on the anti-tumor and ear protection effect of RG108 tetravalent platinum in mice. The specific method is as follows: 3-4 week old BALB / c-nu athymic nude female mice were selected, and 5×10 Fadu cells were made. 6 / ml cell suspension, take 100 μL and inject it subcutaneously into the armpit of the mouse. When the tumor grows to 100 mm 3 Afterwards, the mice were randomly divided into four groups: saline, RG108, cisplatin / oxaliplatin, RG108 monosubstituted tetravalent platinum / RG108 disubstituted tetravalent platinum. The mice were given drugs once every two days for seven times. The weight of the mice and the growth and development of the tumor were recorded. The mice were killed the day after the last drug administration. The tumor and liver and kidney tissues were taken and the tumor volume and weight were recorded. The results are as follows Fig.15 shown.
[0105] Fig.15 In the figure, a is a graph showing the changes in tumor volume over time in the cisplatin tetravalent platinum group substituted with RG108, b is a graph showing the changes in tumor volume over time in the oxaliplatin tetravalent platinum group substituted with RG108, c is a graph showing the changes in body weight of mice in the cisplatin tetravalent platinum group substituted with RG108, and d is a graph showing the changes in body weight of mice in the oxaliplatin tetravalent platinum group substituted with RG108.
[0106] Among the cisplatin tetravalent platinums substituted by RG108, the tumor volume of the RG108 cisplatin dual-substituted group was the smallest, which was 2 / 3 of that of the model group, and there was no significant difference in the weight of mice compared with other groups, indicating that the RG108 cisplatin dual-substituted group had the best anti-tumor effect and no obvious toxicity. Among the oxaliplatin tetravalent platinums substituted by RG108, the tumor volume of the oxaliplatin group was slightly smaller than that of the oxaliplatin tetravalent platinum substituted by RG108, and the oxaliplatin tetravalent platinum substituted by RG108 had no obvious anti-tumor advantage.
[0107] ABR (brainstem evoked potential) was used to test the hearing of mice. Mice were intraperitoneally injected with 3% sodium pentobarbital (30 mg / kg). After anesthesia took effect, needle electrodes were inserted. The recording electrode was inserted into the middle of the front skull, penetrated the skin to the skull periosteum, and placed at the midpoint of the coronal suture. At the same time, the reference electrode and the ground electrode were inserted into the subcutaneous tissue behind the sound-giving ear and the contralateral ear. TDH-39 headphones were used to give sound, and the sound source was 5 cm away from the auricle. The evoked potential was processed by a signal processor for superposition and testing: the stimulus sound was alternating short sounds (clicks), with a repetition rate of 10 times / second. The main parameters selected for the experiment were: band filtering of 4KHz, 8KHz, 12KHz, 16KHz, 24KHz, 32KHz, scanning time of 10ms, and superposition of 512 times.
[0108] The test sound intensity starts at 90 dBSPL, and decreases by 5 dBSPL when approaching the threshold. The electrophysiological response is elicited by the needle electrode, and after amplification and processing, it is displayed on the fluorescent screen in the form of a waveform. The threshold is represented by the sound intensity of wave III in the brainstem potential wave group that can just be recognized by the naked eye. The ABR recorded by a normal mouse is composed of 4-6 waves, among which wave III has the largest amplitude and disappears last. Moreover, wave III has good repeatability and is relatively stable. Therefore, wave III can be used as the main wave of the mouse ABR wave group. This experiment mainly determines the reaction threshold of wave III as the ABR threshold of the experimental animal. After recording the threshold values measured at each frequency, the mouse is placed in a cage. The results are as follows: Fig.16 As shown, among the cisplatin tetravalent platinum substituted by RG108, the hearing thresholds of the RG108 double-substituted cisplatin group at 16KHz and 24KHz were statistically different from those of the cisplatin group, indicating that the cisplatin tetravalent platinum substituted by RG108 can alleviate the ototoxicity induced by cisplatin. Among the oxaliplatin tetravalent platinum prodrug substituted by RG108, there was no significant difference between the oxaliplatin group and the oxaliplatin tetravalent platinum substituted by RG108, which may be due to the weak ototoxicity of oxaliplatin, so the relief effect of the oxaliplatin tetravalent platinum substituted by RG108 is not obvious.
[0109] Fig.16 In the figure, a is a graph showing the change of ABR threshold of mice in the cisplatin tetravalent platinum group substituted with RG108 as a function of frequency, and b is a graph showing the change of ABR threshold of mice in the oxaliplatin tetravalent platinum group substituted with RG108 as a function of frequency.
[0110] Example 9 Experiment on platinum accumulation and hepato-renal toxicity of mice with RG108 tetravalent platinum: After the mice in Example 8 were given the drug, they were anesthetized and blood was taken before being killed. Serum was collected and the concentrations of albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total protein (TP), serum creatinine (Scr), and urea nitrogen (BUN) in the serum were detected using an automatic blood biochemical analyzer. The liver, kidney, tumor, and cochlea were fixed with a fixative, embedded in paraffin, and sectioned. They were stained with HE and subjected to histological analysis. Liver, kidney, tumor, and cochlear tissues were collected, and the accumulated platinum content in the tissues was detected by ICP-MS. The results are as follows: Fig.17 As shown, RG108 tetravalent platinum exhibits a high platinum accumulation capacity in tumors, while the accumulation in the liver, kidney, and cochlea is relatively low.
[0111] Fig.17 In the figure, a is the graph of the accumulated platinum content in the liver of the RG108 substituted cisplatin tetravalent platinum group, b is the graph of the accumulated platinum content in the kidney of the RG108 substituted cisplatin tetravalent platinum group, c is the graph of the accumulated platinum content in the tumor of the RG108 substituted cisplatin tetravalent platinum group, and d is the graph of the accumulated platinum content in the cochlea of the RG108 substituted cisplatin tetravalent platinum group.
[0112] like Fig.18 and Fig.19 As shown in the figure, the serum indexes and HE results were found to be the most significant damage in the liver tissue in the cisplatin group, while the RG108 tetravalent platinum group did not show obvious liver toxicity. Compared with the Pt group, the RG108 tetravalent platinum group was able to enhance the glomerular filtration function, protect the kidneys and prevent them from being damaged.
[0113] Fig.18 In the figure, a is the content graph of alanine aminotransferase (ALT) in RG108 substituted cisplatin tetravalent platinum group mice, b is the content graph of aspartate aminotransferase (AST) in RG108 substituted cisplatin tetravalent platinum group mice, c is the content graph of alkaline phosphatase (ALP) in RG108 substituted cisplatin tetravalent platinum group mice, d is the content graph of total protein (TP) in RG108 substituted cisplatin tetravalent platinum group mice, e is the content graph of serum creatinine (Scr) in RG108 substituted cisplatin tetravalent platinum group mice, f is the content graph of urea nitrogen (BUN) in RG108 substituted cisplatin tetravalent platinum group mice, g is the content graph of albumin (ALB) in RG108 substituted cisplatin tetravalent platinum group mice.
[0114] In summary, RG108 tetravalent platinum can passively target tumor sites, increase drug uptake by tumor cells, reverse tumor growth and kill tumors through DNA methylation, while also alleviating cisplatin-induced hepatotoxicity, renal toxicity and ototoxicity, thereby playing a synergistic anti-tumor effect.
[0115] The present invention synthesized RG108 tetravalent platinum for the first time. This small molecule solves the shortcomings of poor water pharmacokinetics and congenital or acquired drug resistance of platinum drugs, and alleviates the problems of toxic side effects such as ototoxicity, hepatotoxicity and renal toxicity caused by platinum. The simple and efficient synthesis and preparation process makes RG108 tetravalent platinum not only economical and practical, but also mass-produced, providing the possibility for clinical transformation. RG108 tetravalent platinum preparations can increase the drug uptake capacity of tumor cells, can passively target the tumor site, and have a good anti-tumor effect.
[0116] The specific implementation of the present invention described above does not constitute a limitation on the protection scope of the present invention. Any other corresponding changes and modifications made based on the technical concept of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A RG108 tetravalent platinum, characterized in that: The RG108 tetravalent platinum is obtained by connecting and coordinating RG108 with a platinum compound, wherein the platinum compound is cisplatin or oxaliplatin; The RG108 tetravalent platinum is selected from a single R platinum complex containing one RG108 group or a double R platinum complex containing two RG108 groups; The general structural formula of the single R platinum complex is: ; The general structural formula of the double R platinum complex is: ; Wherein, the R is a RG108 group, and the RG108 group is: 。 2. The RG108 tetravalent platinum according to claim 1, characterized in that The RG108 tetravalent platinum is one of the following structural formulas: 。 3. A method for preparing RG108 tetravalent platinum according to claim 1, characterized in that: The following steps are involved: S1. Synthesis of Hydroxyplatinum Weigh cisplatin or oxaliplatin, slowly add hydrogen peroxide, protect from light, heat and reflux at 75°C for 4 hours, after the reaction is completed, stand at 5°C for crystallization, centrifuge, wash the solid after centrifugation with distilled water, ethanol, and ether twice each, and dry to obtain yellow solid cisplatin hydroxyplatin and white solid oxaliplatin hydroxyplatin; Synthesis of tetravalent platinum S2 and RG108 Synthesis of Disubstituted Tetravalent Platinum with S21 and RG108 Weigh the cisplatin hydroxyplatinum or oxaliplatin hydroxyplatinum, add the solvent DMF, then add RG108, triethylamine and TBTU in sequence, protect from light, under nitrogen protection, stir at room temperature until the reaction liquid is clear, add ice water to the reaction liquid to precipitate a yellow precipitate, and filter to obtain RG108 disubstituted cisplatin or RG108 disubstituted oxaliplatin; Synthesis of Monosubstituted Tetravalent Platinum with S22 and RG108 Add RG108, triethylamine and TBTU to DMSO, stir at room temperature for 20 minutes, then add the cisplatin hydroxyplatinum or oxaliplatin hydroxyplatinum, protect from light, stir at room temperature under nitrogen protection until the reaction solution is clear, add ice water to the reaction solution to precipitate a yellow precipitate, and filter to obtain RG108 monosubstituted cisplatin or RG108 monosubstituted oxaliplatin; S3, RG108 Purification of tetravalent platinum Method 1 RG108 mono-substituted cisplatin, RG108 di-substituted cisplatin and RG108 di-substituted oxaliplatin were purified by silica gel column, and gradient eluted with a mixture of dichloromethane and methanol to obtain RG108 tetravalent platinum; Method 2 The RG108 monosubstituted oxaliplatin was washed twice with methanol and twice with dichloromethane to obtain RG108 tetravalent platinum.
4. The method for preparing RG108 tetravalent platinum according to claim 3, characterized in that: In step S1, the molar ratio of the cisplatin or the oxaliplatin to the hydrogen peroxide is 1:43.
84.
5. The method for preparing RG108 tetravalent platinum according to claim 3, characterized in that: In step S1, the mass concentration of hydrogen peroxide is 30%.
6. The method for preparing RG108 tetravalent platinum according to claim 3, characterized in that: In step S21, the molar ratio of the cisplatin hydroxyplatinum or the oxaliplatin hydroxyplatinum to RG108, triethylamine and TBTU is 1:3:3:3; in step S22, the molar ratio of the cisplatin hydroxyplatinum or the oxaliplatin hydroxyplatinum to RG108, triethylamine and TBTU is 1.1:1:3:
3.
7. The method for preparing RG108 tetravalent platinum according to claim 3, characterized in that: In step S3, the volume ratio of dichloromethane to methanol in the dichloromethane and methanol mixture is 15:
1.
8. Use of the RG108 tetravalent platinum according to claim 1 in the preparation of anti-tumor drugs, hearing protectants, and liver and kidney protectants.
9. The use of RG108 tetravalent platinum according to claim 8 in the preparation of anti-tumor drugs, hearing protectants, and liver and kidney protectants, characterized in that: The tumors include non-small cell lung cancer, cervical cancer, breast cancer, pharyngeal squamous cell carcinoma, colon cancer and liver cancer cells.
